Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting the deadly Nipah virus. The trial involves 51 participants aged 18 to 55. Funded by the Coalition for Epidemic Preparedness Innovations…
#oxfordvaccinegroup #cepi #nipah #southeastasia #singapore #malaysia #niv #astrazenecaplcazn #modernainc #usus